Open AccessPharmacodynamic evaluation of piperacillin/tazobactam versus meropenem against extended-spectrum β-lactamase-producing and non-producing Escherichia coli clinical isolates in a hollow-fibre infection model
Author(s) -
Kamrul Islam,
Fekade Bruck Sime,
Steven C. Wallis,
Michelle J. Bauer,
Brian M. Forde,
Patrick N A Harris,
Tahmina Shirin,
Zakir Hossain Habib,
Meerjady Sabrina Flora,
Jason A. Roberts
Publication year - 2022
Publication title -
the journal of antimicrobial chemotherapy/journal of antimicrobial chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.124
H-Index - 194
eISSN - 1460-2091
pISSN - 0305-7453
DOI - 10.1093/jac/dkac186
Subject(s) - meropenem , piperacillin , piperacillin/tazobactam , tazobactam , microbiology and biotechnology , escherichia coli , antibiotics , medicine , pharmacodynamics , beta lactamase inhibitors , regimen , biology , antibiotic resistance , bacteria , pharmacokinetics , imipenem , pseudomonas aeruginosa , biochemistry , genetics , gene
Urosepsis caused by extended-spectrum β-lactamase (ESBL)-producing Escherichia coli is increasing worldwide. Carbapenems are commonly recommended for the treatment of ESBL infections; however, to minimize the emergence of carbapenem resistance, interest in alternative treatments has heightened.